Bros. Advisors Lp Baker Purchases 310,559 Shares of KALA BIO, Inc. (NASDAQ:KALA) Stock

KALA BIO, Inc. (NASDAQ:KALA) major shareholder Bros. Advisors Lp Baker acquired 310,559 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The stock was acquired at an average price of $6.44 per share, with a total value of $1,999,999.96. Following the completion of the acquisition, the insider now directly owns 1,083,398 shares of the company’s stock, valued at $6,977,083.12. This represents a 40.18 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

KALA BIO Stock Performance

KALA traded up $0.07 during trading on Tuesday, hitting $6.94. The stock had a trading volume of 25,347 shares, compared to its average volume of 77,397. The company has a current ratio of 2.15, a quick ratio of 2.15 and a debt-to-equity ratio of 3.18. KALA BIO, Inc. has a 12 month low of $4.21 and a 12 month high of $9.25. The company has a 50 day simple moving average of $6.60 and a 200-day simple moving average of $6.24. The firm has a market cap of $31.99 million, a PE ratio of -0.56 and a beta of -2.15.

KALA BIO (NASDAQ:KALA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.93) earnings per share for the quarter, topping the consensus estimate of ($2.43) by $0.50. Analysts expect that KALA BIO, Inc. will post -10.84 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of KALA BIO in a report on Friday, November 15th.

Institutional Investors Weigh In On KALA BIO

A hedge fund recently bought a new stake in KALA BIO stock. SR One Capital Management LP purchased a new stake in KALA BIO, Inc. (NASDAQ:KALA) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO accounts for about 1.0% of SR One Capital Management LP’s investment portfolio, making the stock its 9th largest position. SR One Capital Management LP owned approximately 15.76% of KALA BIO as of its most recent SEC filing. Institutional investors own 24.61% of the company’s stock.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.